Phase I and Pharmacokinetic Study of Escalating

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile o...

2 downloads 0 Views 137KB Size

Recommend Documents

May 15, 2009 - Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour ... Authors' Affiliations: 1Institute for Drug Development, Cancer Therapy ...

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

Dec 15, 2005 - Anthony W.Tolcher,1and Eric K. Rowinsky1. Abstract Purpose:To ...... Tricoli JV, Sahai BM, McCormick PJ, Jarlinski SJ,. Bertram JS, Kowalski D.

Abstract. Purpose: VNP40101M is a novel sulfonylhydrazine al- kylating agent with broad antitumor activity in animal mod- els. As alkylating agents are ...

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

treatment of multiple myeloma, ovarian cancer, breast cancer, and neuroblastoma (3–5). .... ferases, -glutamyl-aminotransferase, alkaline phosphatase, and.

In a phase 2 study of raltitrexed, cisplatin, and 5- fluorouracil administered to .... nitroacetanilide, was obtained from Sigma-Aldrich (Milwaukee,. WI). Twenty-five ...

Apr 20, 2010 - Blood sampling for PK and drug-drug interaction studies was done. ... trabectedin every 2 weeks in patients with advanced solid tumors. J Clin.

were no DLTs in the six patients evaluated at the first two dose levels of 600 and 900 g/m2. Reversible grade 4 transaminitis occurred in two of nine patients after ...

staurosporine family of agents, which have two indole nitrogens linked to a carbohydrate residue. Representatives from both of these subgroups have been the ...

Oct 13, 2009 - pared with prior studies of the parental antibody hu3S193. These results ... humanized monoclonal antibody based on the anti-Ley anti-.

infusion solutions are compatible with PVC i.v. infusion bags and are chemically stable ... two cycles of treatment. Disease assessments by any tech- ...... Click on "Request Permissions" which will take you to the Copyright Clearance Center's.

Apr 9, 2017 - to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.

ever, the high systemic levels of resveratrol conjugate metabolites ...... Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. Metabolism and ...

Apr 13, 2017 - Clinical Laboratory Improvement Amendments (CLIA)- certified laboratory using ..... mediated cytotoxicity in NSCLC cells (16, 27), in which.

SU11654, using a canine model of spontaneous tumors. This .... mous cell carcinoma, mammary carcinoma, and lymphoma. Additional eligibility ..... lomustine.

Aug 1, 2007 - the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24: 1491 ^ 8. 39. Himmelstein KJ, PattonTF, Belt RJ ...

Nov 15, 2013 - originally isolated from Streptomyces platensis, which strong- ly inhibits hypoxia-induced vascular endothelial growth factor expression and cell ...

Dec 3, 2010 - anti-phospho-histone H3 (pHH3) antibody (Cell Signaling Technology, ... tumor response and pHH3 immunohistochemistry in keratinocytes.

Oct 15, 2008 - toxicities were transaminitis, fatigue, atrial fibrillation, raised serum creatinine, and hyperbilirubine- mia. A patient with pancreatic cancer treated ...

modification of the catharanthine moiety of vinblastine resulting in less neurotoxicity and major anti-tumor activity. Vinorelbine inhibits microtubule assembly, and.